|
By Jay Myers
In February 3-5, 2010, CHI's Molecular Medicine Tri-Conference was held in San Francisco at the Moscone Center. There were around 3,000 attendees at this year's conference with over 1,223 participating companies. Our interest area at this conference was mainly about Personalized Medicine (PM). We attended a number of PM sessions.
Richard Ding, CEO at BioTheranostics, said PM is progressing, but there is no clear path defined as a business model. There are success factors such as Warfarin and K-Ras. Diagnostics companies face a number of challenges in developing companion diagnostics, he said. He also discussed his four elements for success with PM test development that included: achieve clinical validity, demonstrate clinical utility, deliver economic value, and establish analytical validity. He said the need for PM is evident because of the toxicity challenge. There are few diagnostic tests on the market, according to Ding.
The panel discussion,"Health IT: What Will Success Look Like?" brought up some interesting points. Panelist Joseph Miller from the CDC said the first step to enable Personalized Medicine is to gather digitized data, however we can't seem agree on the technology. Wayne Rosenkrans, Chairman and President, of the Personalized Medicine Coalition, said he calls it Personalized Healthcare. They have moved away from calling it
|
|
